


Looking back to the way(s) taken by EU....

Tomas Salmonson, PhD Former chair, CHMP, EMA

Regulatory Workshop, Moscow, October 2019




Post Nov 2005 Three European Systems






The European medicines regulatory network




~ 50 national regulatory authorities European Commission European Medicines Agency








Working Parties and other Groups






CHMP Working Parties and Expert Groups






Committee for Human Medicinal Products






Rapporteurships 01/2015 – 02/2017









CHMP Voting Rules



No pre-determined MS position CHMP capacity scientific member, hence vote personal / individual

CHALLENGES FACING REGULATORS TODAY....

- New drugs are often considered expensive
 - Hep C scientific success, public health...
 - Expensive drug development. Why? GCP?
 - Combinations
 - Due to cost, drugs are often used in a more restricted population than the entire indication
- Involvement of "health care providers"
- Who provides information to patients and prescriber today? Dr GOOGLE? YouTube?
- Involvement of patients

INVOLVMENT OF PATIENTS... (NOT AN EASY STORY...)

- Why?
 - Transparency?
 - PROs (Patient reported outcomes)
 - Input in decision making?
 - Quality Assurance of information?
- Homś
 - Members of Committees?
- Conflict of Interests?

TODAY....

- Regulators are part of a health care system
 - Different regulatory agencies have different tasks.
 - Links to HTA/Payers and other stakeholders
- Drug development is global, information is available to everyone.
- Regulatory output: an approval with a SmPC (including an indication) is not enough. The package leaflet is....EPARs!!!
- Structured B/R section in the CHMP Assessment report.
- Uncertainties are more clearly identified and recognizes today.

Benefit-Risk structure – a part of transparency

5.1Therapeutic context

- 5.1.1 Disease or condition
- 5.1.2 Available therapies and unmet medical need
- 5.1.3 Main clinical studies
- **5.2 Favourable effects**
- 5.3 Uncertainties/limitations of favourable effects
- **5.4 Unfavourable effects**
- 5.5 Uncertainties/limitations of unfavourable effects
- **5.6 Effects Table**
- 5.7 Benefit-risk assessment and discussion
 - 5.7.1 Importance of favourable and unfavourable effects
 - 5.7.2 Balance of benefits and risk
 - 5.7.3 Additional considerations



approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • guidelines • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • inspection laboratory analysis • market surveillance • medicinal products • medical devices • approvals • authorisation • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • approvals • authorisation

ALL THIS IS GOOD BUT.....


THE SITUATION TODAY.....

- Drug development a recognized joint venture ("private-public partnership")!
- Science continues to deliver new drugs
 - ATMPs, biologics, small molecules
 - Combinations of drugs
 - Disease modifying/cure rather than symptomatic relief
- Many (!) new drugs fall within the scope of the Orphan legislation
- Some drugs are (initially) approved with narrow indications ...
- The post-approval development is more and more important
 - Conditional, "Annex II" conditions
 - How well is the PIP working?




20 years of EMA

20 years of EMA







CONCLUSIONS.....(FROM THE EU EXPERIENCE)

- MS responsible for scientific assessments
 - Joint scientific standards (Scientific advice, guidelines (EU and ICH)
 - Topic specific "Working parties"
 - Benefit-Risk structure transparency
 - Two assessment reports
- All MS taking part in the decision-making process
- Patchwork of legislations....need to update:
 - Orphan including COMP?
 - Pediatrics including PDCO?
 - Conditional Marketing Approvals?
 - Advance therapies?
- Challenge the value of other regulatory tools such as:
 - Accelerated timetable
 - "PRIME"
 - Content of PIP:s
 - etc



?Questions?

Regulatory Workshop, Moscow, October 2019